Randomised phase 2 trial in 109 patients with recurrent glioblastoma: tislelizumab plus low-dose bevacizumab gave a median overall survival of 13.3 months versus 6.6 months in the control group, with no grade 4 adverse events in the experimental group.
RCTn = 109
Zhang et al. Dynamic signature for the effectiveness of anti-PD-1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial